Business · 31/01/2000Updated: 10/17/2026 · 1 min read
FDA Determines Regulatory Review Period for Certiva TM Patent Extension
Summary
The Food and Drug Administration has officially confirmed the regulatory review period for Certiva TM, a human biological product, in accordance with federal regulations, following a submission to the U.S. Patent and Trademark Office.
Original source language: Federal Register — Food and Drug AdministrationOpen original release →